Veritas International utilizes whole exome and genome sequencing to provide detailed genetic insights that help individuals assess their risk for hereditary diseases and inform preventive healthcare strategies. By offering physician-assisted genetic counseling, the company ensures that clients receive tailored recommendations and actionable plans based on their unique genetic profiles.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Individuals often lack comprehensive insights into their genetic predispositions for hereditary diseases, hindering their ability to make informed decisions about preventive healthcare. Traditional methods may not offer the depth of analysis needed to fully understand potential risks and implement proactive strategies.
Solution
Veritas International offers a suite of genetic tests, including whole exome and genome sequencing, to provide individuals with detailed insights into their risk for hereditary diseases. Their services encompass preventive medicine, perinatal medicine, and diagnostic genomics, enabling proactive healthcare management. The company emphasizes physician-assisted genetic counseling to ensure clients receive tailored recommendations and actionable plans based on their unique genetic profiles. By analyzing a comprehensive set of genes, Veritas empowers individuals and their healthcare providers to make informed decisions about disease prevention, early detection, and personalized treatment strategies.
Target Audience
The primary target audience includes healthy individuals seeking proactive healthcare management, couples planning a family, and medical professionals looking to provide advanced genetic insights to their patients.
Features
- Whole exome and genome sequencing for comprehensive genetic analysis
- Preventive genetic tests for assessing risk of common diseases like cardiovascular disease and cancer
- Non-invasive prenatal testing (NIPT) to screen for chromosomal abnormalities
- Neonatal screening tests for early detection of childhood-onset diseases
- Polygenic risk screening for common multifactorial diseases
- Genetic counseling services to support pre- and post-test decision-making
- Analysis of genes related to metabolism to understand the effect of drugs on the patient (Pharmacogenomics)
- Option to extend the study to other genes of interest